Home — The Jenner Institute

A new Oxford consortium to develop novel therapies for Tuberculosis

Speaking at the event, 'The Nobel Prize to Now: building a legacy of discovery to tackle AMR', Prof McShane reflects on why we so urgently need new antibiotics to treat drug-resistant tuberculosis, and how therapeutic vaccines can be used to combat the world's most devastating pathogen. To tackle this global health threat, the IOI has awarded £5m for the establishment of an Oxford consortium to develop new therapies for TB.

‘Single shot’ malaria vaccine delivery system could transform global immunisation

A team of scientists at the Jenner Institute, Institute of Biomedical Engineering and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have developed programmable microcapsules to deliver vaccines in stages, potentially eliminating the need for booster shots and increasing immunisation coverage in hard-to-reach communities.

Jenner Early Researchers Symposium 2025

On Monday 23 June the Jenner Institute hosted the 3rd annual Jenner Early Researchers Symposium at Pembroke College. This event is committed to providing a friendly environment for DPhil and Master’s students, research assistants and technicians to present their work and engage in the research of their peers.

R21/Matrix-M vaccine receives Galien Foundation prize for Best Public Sector Innovation

The R21/Matrix-M vaccine has received The Galien Foundation prize for Best Public Sector Innovation. Members of the Jenner Institute team, Prof Sir Adrian Hill, Mehreen Datoo and Lisa Stockdale were present during The Galien Foundation UK Forum & Awards Ceremony in London on 5th June 2025.

Head of trailblazing clinical research facility in Burkina Faso visits Oxford

Professor Halidou Tinto visited the Jenner Institute and gave a seminar on the international partnerships for health research in Africa. He told the story of how he created the first clinical research facility in Burkina Faso. The renowned Clinical Research Unit of Nanoro plays a crucial role in the fight against malaria and his team led the phase I/IIb clinical trial for the R21/Matrix-M malaria vaccine developed at the Jenner Institute.

Shipment of R21 malaria vaccine to Central African Republic marks latest milestone for child survival

Last month, UNICEF delivered over 43,200 doses of the R21/Matrix-M malaria vaccine developed through collaboration between Oxford University’s Jenner Institute and Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology, by air to Bangui, Central African Republic, with further shipment of about 163,800 doses to follow, which is allocated for children in the CAR currently.

Côte d’Ivoire makes history as first nation to deploy R21/Matrix-M™ Malaria Vaccine

Today marks the official rollout of the new R21/Matrix-M™ malaria vaccine - co-developed by the University of Oxford and Serum Institute of India, leveraging Novavax’s Matrix-M™ adjuvant technology. In a historic step in the battle to beat malaria, the first official vaccination is due to take place in Abidjan, Côte d’Ivoire, this morning and will be subsequently rolled-out in 38 districts across the country.

The Jenner Institute Early Researchers Symposium 2024

On June 7, 2024, the second annual Jenner Institute Early Researchers Symposium (JERS) was held at St Anne's College, bringing together a vibrant community of over 80 DPhil Students, Research Assistants, Technicians and Apprentices from across the Nuffield Department of Medicine to network, share their research and discuss career aspirations.

Jenner Institute director receives award for an Outstanding Contribution to Translational Medicine

The Director of the Jenner Institute, Professor Sir Adrian Hill, was announced as the 2024 recipient of the UK Association of Physicians’ award for an Outstanding Contribution to Translational Medicine. He was presented with the award at a ceremony during the annual meeting held in Newcastle 23-24 May, 2024.

Vice-Chancellor's Award for R21 Malaria vaccine team

The R21/Matrix-M Malaria vaccine clinical development programme team from the Jenner Institute has won the Innovation and Commercialisation category of the University of Oxford Vice-Chancellor’s Awards 2024. The team, led by Prof. Sir Adrian Hill, is behind the clinical development of the R21 Malaria vaccine which is due to be rolled out in the first African countries in the next months. The Vice-Chancellor’s Awards recognise the achievements and celebrate success across the University.

Scientists receive the European Hector Research Award for HIV

The AELIX-002 study group research was awarded the European Hector Research Award in HIV for research on the therapeutic vaccine against HIV. The researchers include Prof Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute at NDM.

Oxford R21/Matrix-M™ malaria vaccine receives WHO recommendation for use paving the way for global roll-out

The highly effective vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant is critical to reducing over half a million malaria-related deaths annually.

Oxford malaria vaccine receives regulatory clearance for use in Burkina Faso

The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Burkina Faso by the country’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).

African Phase I HIV vaccine trial shows encouraging preliminary results

The clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully. Preliminary analysis of the trial results demonstrates the induction of high frequencies of broadly specific T cells that recognise functionally conserved regions on HIV-1 and are therefore more protective.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.

History of the COVID-19 vaccine

The Oxford / AstraZeneca COVID-19 vaccine is estimated to have saved more than six million lives – more than any other COVID vaccine, during the first year of use.

Find out more

Support us

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

Make a gift

Publications

Development and Evaluation of Compact Semi-Synthetic Promoters for Enhanced Antigen Expression in Adenoviral-Vectored Vaccines

Hlaváč M. et al, (2026), Vaccines, 14, 260 - 260

Protocol for precision cutting and short-term culture of lymph node tissue slices for modeling of innate immune responses ex vivo.

Fergusson JR. et al, (2026), STAR Protoc, 7

The effect of pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine on nasopharyngeal colonisation following human infection challenge with serotype 3 and serotype 6B (PREVENTING PNEUMO 2): a double-masked, randomised, controlled, phase 4 trial

Liatsikos K. et al, (2026), The Lancet Microbe, 7, 101267 - 101267

Latest News

Get regular updates on social media.

Seminars

More seminars

Cookies on this website